Invizius Closes £5.3M Series A Financing
Invizius Limited, a Motherwell, Scotland, UK-based biotechnology company developing treatments to suppress unwanted innate immune responses, closed Series A financing of £5.3m. The round was led by existing investors Mercia, Downing Ventures, Old College Capital, Scottish Enterprise, Solvay Ventures and new investors Calculus Capital and experienced life science entrepreneur and investor, Dr Jonathan Milner. The Series A remains open to other investors until June 2021. The company intends to use the funds to complete a First-in-Man safety study in 2022 of its H-Guard ® Priming Solut...